ExtraCorporeal Membrane Oxygenation (ECMO) Clinical Trial
— AQUAOfficial title:
Evaluation of Quality of Life and Its Influencing Factors After VA-ECMO in Refractory Cardiac Arrest Based on SF-36 Score : A Grenoble Cohort Study From 2006 Through 2018
| Verified date | December 2020 |
| Source | University Hospital, Grenoble |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
If the ExtraCorporeal Membrane Oxygenation (ECMO) improves survival in the management of refractory cardiac arrest (RCA), this technique is still an invasive technique, not devoid of complications and requiring intensive care that can have serious consequences for patients. If the studies so far show an acceptable quality of life post ECMO in refractory cardiac arrest, the study looks about the quality of life of our patients in Grenoble who survived a refractory cardiac arrest between 2006 and 2018 at the hospital university Grenoble Alps and the factors influencing this quality of life.
| Status | Completed |
| Enrollment | 75 |
| Est. completion date | April 27, 2021 |
| Est. primary completion date | January 15, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Adult >18 years - Admission to intensive care unit after a Refractory Cardiac Arrest - Hemodynamic instability after resumption of spontaneous cardiac activity. - Non-opposition of the patient or his relatives - Admission to intensive care unit From 2006 Through 2018 Exclusion Criteria: - ECMO for hypothermia or drug intoxication. - Comorbidity contraindicated the ECMO - Patients dead before hospital discharge |
| Country | Name | City | State |
|---|---|---|---|
| France | Chu Grenoble Alpes | Grenoble |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Grenoble |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Global quality of life score | Items from the SF36 (Short Form 36) survey | Through study completion, an average of 3 months | |
| Secondary | Live patients characteristics description | Demographic and clinical retrospective data collection | Through study completion, an average of 3 months | |
| Secondary | Vital status | Deed/Lived | Through study completion, an average of 3 months | |
| Secondary | Quality of life score related at live patients characteristics description | Items from the SF36 (Short Form 36) survey matched with live patients characteristics description | Through study completion, an average of 3 months | |
| Secondary | Quality of life score comparison | Items from the SF36 (Short Form 36) survey compared between the 2 groups ( RCA with /without ECMO) admitted from january 2015 and december 2018 | Through study completion, an average of 3 months |